Impact of the UK COVID-19 pandemic on HbA1c testing and its implications for diabetes diagnosis and management

David Holland¹, Adrian Heald², Mike Stedman³, Lewis Green⁴, Jonathan Scargill⁵, Christopher Duff⁶, Fahmy Hanna⁷, Pensee Wu⁸, Ian Halsall⁹, Neil Gaskell¹⁰, and Anthony Fryer¹¹

¹The Benchmarking Partnership
²Salford Royal Hospitals NHS Trust
³Res Consortium
⁴Whiston Hospital
⁵Salford Royal Hospital
⁶University Hospitals of North Midlands
⁷University Hospitals of North Midlands NHS Trust
⁸Affiliation not available
⁹Addenbrooke’s Hospital
¹⁰Warrington and Halton Hospitals NHS Foundation Trust
¹¹Keele University

December 11, 2020

Abstract

Our findings illustrate the widespread collateral impact of implementing measures to mitigate the impact of COVID-19 in people with, or being investigated for diabetes mellitus (DM). Ironically, failure to focus of the wider implications for people with DM and other groups with long-term conditions, may place them at increased risk of poor outcomes from SARS-CoV-2 infection itself, irrespective of the implications for their longer-term health prospects.

Hosted file

HbA1c testing during covid-19 Dec2020.pdf available at https://authorea.com/users/382431/articles/498332-impact-of-the-uk-covid-19-pandemic-on-hba1c-testing-and-its-implications-for-diabetes-diagnosis-and-management